In the seventh and final episode of the Clinical Trial podcast series, you can hear Prof. Konstanze Döhner and Prof. Antonio Almeida exchanging ideas and thought-provoking opinions about how investigator-initiated clinical trials and new trial designs can provide patients early access to novel drugs.
They discuss the importance of large collaborative groups, the complexity of current requirements that must be in place, and the impact that these challenges may have, along with the relevant issues that could be changed in order to enable more uncomplicated participation and conduction of clinical studies.
In this series of Clinical Trial podcasts produced by EHA, experts unravel for you the many issues linked to the design and execution of a clinical study, complementing the information present in our Clinical Trial Map.
It will help you answer interrogations such as:
• What is a CRO?
• How are clinical studies designed?
• Which role(s) should sponsors fulfil?
Experts will talk directly to you to give you an overview of several essential clinical research topics in a series of 6 podcasts.
Host: Prof. Konstanze Döhner; Prof. Antonio Almeida
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more podcasts or check out the Clinical Trial Map? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
You Might Like
